|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pantuck AJ, Zisman A and Belldegrun AS:
The changing natural history of renal cell carcinoma. J Urol.
166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DiBiase SJ, Valicenti RK, Schultz D, Xie
Y, Gomella LG and Corn BW: Palliative irradiation for focally
symptomatic metastatic renal cell carcinoma: Support for dose
escalation based on a biological model. J Urol. 158:746–749. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gurtan AM and Sharp PA: The role of miRNAs
in regulating gene expression networks. J Mol Biol. 425:3582–3600.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V and Lee RC: Identification of
microRNAs and other tiny noncoding RNAs by cDNA cloning. Methods
Mol Biol. 265:131–158. 2004.PubMed/NCBI
|
|
7
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu X, Li Y, Shen H, Li H, Long L, Hui L
and Xu W: miR-137 inhibits the proliferation of lung cancer cells
by targeting Cdc42 and Cdk6. FEBS Lett. 587:73–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng Y, Li Y, Liu D, Zhang R and Zhang J:
miR-137 effects on gastric carcinogenesis are mediated by targeting
Cox-2-activated PI3K/AKT signaling pathway. FEBS Lett.
588:3274–3281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu M, Lang N, Qiu M, Xu F, Li Q, Tang Q,
Chen J, Chen X, Zhang S, Liu Z, et al: miR-137 targets Cdc42
expression, induces cell cycle G1 arrest and inhibits invasion in
colorectal cancer cells. Int J Cancer. 128:1269–1279. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y
and He F: MiR-137 targets estrogen-related receptor alpha and
impairs the proliferative and migratory capacity of breast cancer
cells. PLoS One. 7:e391022012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Porta C and Figlin RA:
Phosphatidylinositol-3-kinase/AKT signaling pathway and kidney
cancer, and the therapeutic potential of
phosphatidylinositol-3-kinase/AKT inhibitors. J Urol.
182:2569–2577. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pal SK and Quinn DI: Differentiating mTOR
inhibitors in renal cell carcinoma. Cancer Treat Rev. 39:709–719.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li M, Wang Y, Song Y, Bu R, Yin B, Fei X,
Guo Q and Wu B: MicroRNAs in renal cell carcinoma: A systematic
review of clinical implications (Review). Oncol Rep. 33:1571–1578.
2015.PubMed/NCBI
|
|
18
|
Chen X, Ruan A, Wang X, Han W, Wang R, Lou
N, Ruan H, Qiu B, Yang H and Zhang X: miR-129-3p, as a diagnostic
and prognostic biomarker for renal cell carcinoma, attenuates cell
migration and invasion via downregulating multiple
metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu
X, Xiao P, Shi H, Wang R, Chen L, et al: miR-141 is a key regulator
of renal cell carcinoma proliferation and metastasis by controlling
EphA2 expression. Clin Cancer Res. 20:2617–2630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu R, Ji Z, Li X, Zhai Q, Zhao C, Jiang Z,
Zhang S, Nie L and Yu Z: miR-145 functions as tumor suppressor and
targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J
Cancer Res Clin Oncol. 140:387–397. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kozaki K, Imoto I, Mogi S, Omura K and
Inazawa J: Exploration of tumor-suppressive microRNAs silenced by
DNA hypermethylation in oral cancer. Cancer Res. 68:2094–2105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen L, Wang X, Wang H, Li Y, Yan W, Han
L, Zhang K, Zhang J, Wang Y, Feng Y, et al: miR-137 is frequently
down-regulated in glioblastoma and is a negative regulator of
Cox-2. Eur J Cancer. 48:3104–3111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wiklund ED, Gao S, Hulf T, Sibbritt T,
Nair S, Costea DE, Villadsen SB, Bakholdt V, Bramsen JB, Sørensen
JA, et al: MicroRNA alterations and associated aberrant DNA
methylation patterns across multiple sample types in oral squamous
cell carcinoma. PLoS One. 6:e278402011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Husseinzadeh HD and Garcia JA: Therapeutic
rationale for mTOR inhibition in advanced renal cell carcinoma.
Curr Clin Pharmacol. 6:214–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pantuck AJ, Seligson DB, Klatte T, Yu H,
Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS and Figlin
RA: Prognostic relevance of the mTOR pathway in renal cell
carcinoma: Implications for molecular patient selection for
targeted therapy. Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
|
